Alkem Laboratories block deal: Rs 930 crore sale in 2026

Deal puts Alkem Laboratories in focus

Alkem Laboratories Ltd drew market attention after a sizeable promoter-side stake sale through open market transactions on June 2. About 1.5% of the company’s equity was sold in a block deal valued at around Rs 930 crore, based on exchange data. The deal was executed at Rs 5,200 per share, which was positioned as a floor price in the term sheet referenced in reports. The selling price also implied a discount of about 2.2% to the prior closing price of Rs 5,318. Such transactions typically attract investor focus because they change promoter ownership levels and temporarily increase supply in the stock.

The share price reaction reflected this supply overhang. Alkem Laboratories shares fell 1.42% to close at Rs 5,239 on the National Stock Exchange. The decline extended a downtrend for another session after the stock had already dropped 3.3% in Monday’s session to close at Rs 5,318. Despite the recent weakness, the stock has gained about 4.4% over the past year, while the Nifty 50 has declined around 5.4% over the same period.

What was sold, and at what price

Exchange data showed that nearly 17.88 lakh shares were sold in the transaction. Another data point from NSE block deal figures put the number at 17,88,220 shares, representing a 1.49% stake. The sale price was an average of Rs 5,200 per share, taking the transaction value to about Rs 929.87 crore. Market reports rounded the size to roughly Rs 930 crore.

The block deal followed earlier reports that the Samprada and Nanhamati Family Trust was looking to sell up to a 1.5% stake. According to a term sheet cited in coverage, the trust was represented by authorised individual beneficiaries and sellers Sandeep Singh and Jayanti Sinha. The same term sheet indicated a 90-day lock-up period on any further sale of shares by the sellers.

Promoter sellers: who reduced stake

Two promoter entities were identified as sellers in the transaction: Jayanti Sinha and the Samprada and Nanhamati Singh Family Trust. Jayanti Sinha, part of the promoter group, sold her entire 1.04% shareholding, amounting to 12.38 lakh shares, for Rs 643.87 crore. The Samprada and Nanhamati Singh Family Trust sold 5.5 lakh shares for Rs 286 crore.

Following the stake sale, Jayanti Sinha exited the company, as her entire holding was sold. The sale also reduced overall promoter holding. Reported data showed promoter shareholding dropped to 49.71% from 51.20% after the transaction.

A related disclosure in the same set of reports noted that promoter Sarandhar Singh, on behalf of Samprada and Nanhamati Singh Family Trust, holds an 18.75% stake in Alkem Labs.

Buyers: nine domestic and global investors

On the buying side, nine domestic and global investors were reported to have picked up the shares. The buyers listed included ICICI Prudential Mutual Fund, HDFC Mutual Fund, Edelweiss Mutual Fund, Nippon India Mutual Fund, DSP Mutual Fund, BNP Paribas Arbitrage, Societe Generale, Morgan Stanley Asia Singapore, and Goldman Sachs Bank Europe.

Among them, ICICI Prudential Mutual Fund and HDFC Mutual Fund were the largest buyers. ICICI Prudential Mutual Fund bought 9.03 lakh shares for Rs 469.83 crore, while HDFC Mutual Fund picked up 5.09 lakh shares for Rs 265 crore. DSP Mutual Fund purchased 86,538 shares for Rs 45 crore.

Other named buyers including BNP Paribas Arbitrage, Societe Generale, Nippon India Mutual Fund, Morgan Stanley Asia Singapore, Goldman Sachs Bank Europe, and Edelweiss Mutual Fund each purchased 48,090 shares for Rs 25 crore, based on the deal breakdown in reports.

Price discount and near-term stock move

The transaction price of Rs 5,200 per share carried a discount to the previous closing price of Rs 5,318, reported at about 2.2%. Such discounts are common in large block trades, where sellers prioritise execution certainty and immediate liquidity. The discount level also provides a reference point for the market to assess demand from institutions at that price.

In the immediate aftermath, Alkem shares closed lower at Rs 5,239, down 1.42% on the NSE. This came after the stock had already declined 3.3% in the previous session. While daily moves can be influenced by broader market conditions, a large block sale often adds near-term pressure because of incremental supply and the signalling effect of promoter stake reduction.

What changed in promoter holding

A key measurable outcome was the reduction in promoter ownership. After the divestment, promoter holding fell to 49.71% from 51.20%, according to the exchange-linked data cited. A promoter group member exiting entirely is also notable, as it changes the composition of the promoter shareholding.

Separately, the Samprada and Nanhamati Singh Family Trust continues to be a significant shareholder, with Sarandhar Singh holding 18.75% on behalf of the trust. The combination of these details provides investors clarity on how the sale impacted ownership without changing the company’s operating profile.

Company context investors track

Alkem Laboratories is an Indian pharmaceutical company with operations across domestic formulations, international markets and active pharmaceutical ingredients. The company was described as having a market capitalisation of more than Rs 63,500 crore in the same set of reports.

For investors, the context matters because large ownership changes can influence perceptions around governance, future stake sales, or liquidity. However, the only confirmed near-term follow-through referenced was the term sheet’s 90-day lock-up condition on any further sale of shares by the sellers.

Key data from the block deal

Market impact and why investors care

The immediate market impact was visible in the price decline on the day of the transaction and the extension of a two-session down move. The fact that the stock traded below the prior close after a discounted block deal is consistent with how markets absorb large secondary supply. At the same time, the presence of multiple institutional buyers, including large domestic mutual funds, shows that demand existed at the negotiated price.

From a shareholder perspective, the key confirmed change is the reduction in promoter stake and the exit of Jayanti Sinha. The trade also established a widely observed price reference at Rs 5,200 per share for a sizeable quantity of shares. Over the next few weeks, investors are likely to monitor disclosures and trading patterns for any further large transactions, especially given the mention of a 90-day lock-up period in the term sheet.

Conclusion

Alkem Laboratories saw a promoter-side divestment of about 1.5% equity for roughly Rs 930 crore at Rs 5,200 per share on June 2, with nine domestic and global institutions buying the shares. The stock closed at Rs 5,239 on the NSE, down 1.42% after the deal, and promoter holding fell to 49.71% from 51.20%. The next key data points to watch are any further ownership disclosures and the expiry of the reported 90-day lock-up period referenced in the term sheet.